Scinai Immunotherapeutics Ltd.
Business
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company developing nanosized VHH antibody fragments (NanoAbs) and operating a boutique CDMO. Its main offerings include a pipeline of NanoAb therapeutic candidates for inflammation and immunology indications, an option to acquire PC111 (a monoclonal antibody for dermatological disorders), and contract development and GMP/non‑GMP manufacturing services. The company is organized into two business units: an R&D unit focused on NanoAbs and a CDMO unit branded Scinai Bioservices. It collaborates with academic partners in Germany, provides services to biotech clients globally, and maintains manufacturing capacity in Jerusalem with a U.S. subsidiary for CDMO operations.
Summary from filing dated 2025-05-07
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|
| Research and development. | 6 | 3 | |
| Marketing, general and administrative | 5 | 8 | |
| Other income | — | −12,000 | |
| Total operating loss | 11 | 11 | |
| Financial income, net | −5 | −3 | |
| Net loss | 6 | 8 | |
| Net loss per share attributable to ordinary shareholders, basic (in Dollars per share) | −0.01 | −0.02 | |
| Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic (in Shares) | 754 | 565 |
Consolidated Balance Sheet
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|
| Cash and cash equivalents | 14 | 17 | |
| Restricted cash | 140,000 | 143,000 | |
| Prepaid expenses and other receivables | 155,000 | 326,000 | |
| Total current assets | 14 | 18 | |
| Property, plant and equipment, net | 11 | 12 | |
| Operating lease right-of-use assets | 1 | 2 | |
| Total non-current assets | 13 | 14 | |
| Total assets | 27 | 32 | |
| Trade payables | 716,000 | 999,000 | |
| Operating lease liabilities | 382,000 | 375,000 | |
| Other payables | 1 | 1 | |
| Total current liabilities | 2 | 2 | |
| Warrants liability | 5 | — | |
| Loan from others | 20 | 27 | |
| Non-current operating lease liabilities | 1 | 1 | |
| Total non-current liabilities | 26 | 29 | |
| Ordinary shares of no par value: Authorized: 20,000,000,000 shares at December 31, 2022 and 1,800,000,000 at December 31, 2021; Issued and outstanding 989,290,784 shares at December 31, 2022 and 739,048,544 shares at December 31, 2021 | — | — | |
| Additional paid-in capital | 116 | 113 | |
| Accumulated deficit | −116 | −110 | |
| Accumulated other comprehensive loss | −2 | −2 | |
| Total shareholders equity (deficit) | −2 | 982,000 | |
| Total liabilities and shareholders equity | 27 | 32 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|
| Depreciation of property, plant and equipment | 562,000 | 471,000 | |
| Expense of in-process research and development | 209,000 | — | |
| Financial income related to loan from others | −4 | −3 | |
| Share-based compensation | 2 | 3 | |
| Decrease in other receivables | 140,000 | 59,000 | |
| Changes in operating lease right-of-use assets | 153,000 | 148,000 | |
| Increase (decrease) in trade payables | −175,000 | 3,000 | |
| Changes in operating lease liabilities | −156,000 | −150,000 | |
| Increase in other payables | 309,000 | 644,000 | |
| Net cash used in operating activities | −7 | −7 | |
| Purchase of property, plant and equipment | −836,000 | −139,000 | |
| Net cash used in investing activities | −836,000 | −139,000 | |
| Proceed from issuance of warrants | 6 | — | |
| Proceeds from issuance of shares, net | 932,000 | 21 | |
| Net cash provided by financing activities | 7 | 21 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | −2 | 575,000 | |
| Increase (decrease) in cash, cash equivalents and restricted cash | −3 | 14 | |
| Interest | 916,000 | — | |
| Exercise of warrants liability to equity | 250,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Scinai Immunotherapeutics Ltd.'s CIK number?
Scinai Immunotherapeutics Ltd.'s SEC CIK number is 0001611747 (1611747). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Scinai Immunotherapeutics Ltd.'s SEC filings?
All of Scinai Immunotherapeutics Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.